Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.35 USD
+0.06 (1.82%)
Updated May 28, 2024 04:00 PM ET
After-Market: $3.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Arbutus Biopharma Corporation [ABUS]
Reports for Purchase
Showing records 181 - 190 ( 190 total )
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
3Q15 as Arbutus Prepares for a Busy 2016; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 2This report contains brief updates on the following: DYAX, ANAC, IRWD, ECYT, FATE, XNCR, RGLS, MGNX, FCSC, SNSS, INFI, MDVN, RPTP, SRPT, XOMA, AGTC, EPZM, BLUE, PTCT, CATB, EPRS, ABUS, ICPT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Pipeline Update Sets up for Full 2016; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of October 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of October 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Competitor RNAi Data with Promising Read-through; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $20 Price Target; Casting a Wide Net to Tackle HBV
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $20 Price Target; Casting a Wide Net to Tackle HBV
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H